← Back to headlines
Mereo Downgraded by JP Morgan Due to Setrusumab Regulatory Uncertainty
Mereo BioPharma Group has been downgraded by JP Morgan, citing regulatory uncertainty surrounding its drug setrusumab as the primary reason for the revised rating.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
